Dr. Mohamed Abazeed is an internationally recognized physician-scientist and Chair of Radiation Oncology at Northwestern University Feinberg School of Medicine. His career bridges the disciplines of cancer biology, artificial intelligence, and translational therapeutics, with a research focus on developing predictive tools and mechanistic insights to personalize cancer therapy.

Trained as an MSTP at the University of Michigan (MD/PhD), Dr. Abazeed completed his residency and postdoctoral fellowship at the Harvard Radiation Oncology Program and the Broad Institute, where he led foundational studies in radiogenomics. As an independent investigator, he has pioneered the application of multi-omics and AI to guide individualized radiotherapy, most notably through the development of iGray, an image-based deep learning platform that tailors dose prescriptions to tumor biology. This platform anchors a first-of-its-kind prospective trial that is currently enrolling patients at Northwestern University and is a model for AI deployment in clinical oncology.

Dr. Abazeed’s research has yielded key discoveries in therapeutic resistance, including the role of reversible cell state transitions in small cell lung cancer and large-scale genomic predictors of radiation response. He has authored more than 70 peer-reviewed publications, including work in Nature, The Lancet Digital Health, Nature Communications, and Science Advances. His honors include the NIH R37 MERIT Award, the ASCO Conquer Cancer Foundation Award, and invitations to deliver keynote lectures at international forums.

A dedicated mentor and leader, Dr. Abazeed co-leads Northwestern’s Lung Cancer Program and has shaped educational programs in radiogenomics and AI. His vision is to transform oncology through scientifically grounded, technologically enabled, and patient-centered care.